Immunohistochemical Study on 5-Hydroxytryptamine Immunoreactive Cells in the Alimentary Tract of Bufo melanostictus and Rana nigromaculata

对黑眶蟾蜍(Bufomelanostictus)和黑斑蛙(Rananigromaculata)消化道5-羟色胺免疫活性细胞的形态、分布进行了免疫组织化学定位。5-羟色胺免疫活性细胞在黑眶蟾蜍和黑斑蛙消化道各段中均有分布,分布密度均呈升-降-升-降的波浪式分布特点,二者在幽门部和回肠都有个分布的高峰值。黑眶蟾蜍回肠最高,空肠、幽门部次之,十二指肠、直肠最低;黑斑蛙幽门部最高,回肠、空肠次之,食道、贲门部、直肠最低。5-羟色胺免疫活性细胞位于胃的胃腺上皮、食道及肠的粘膜上皮,有圆形、椭圆形、梭形、楔形等,有的有胞突。文中讨论了5-羟色胺免疫活性细胞分布型的原因及形态与功能的关系。Using immunohistochemical technique, 5-Hydroxytryptamine immunoreactive (5-HT-IR) cells were observed in the alimentary tract of the toad Bufo melanostictus and the frog Rana nigromaculata . 5-HT-IR cells were distributed throughout the alimentary tracts of both species and located in the gastric glands of the stomach regions and in the intestinal or esophageal epithelium with variable frequencies. The density of the cell in B. melanostictus is the highest in the ileum, moderate in the jejunum and stomachus pyloricus, and the lowest in the duodenum and rectum. In R. nigromaculata the density of 5-HT-IR cells is the highest in the stomachus pyloricus, moderate in the ileum and jejunum, and the lowest in the esophagus, stomachus cardiacus and rectum. 5-HT-IR cells were spherical, elliptoid, coniform or spindle-shaped with long cytoplasmic process reaching to the lumen. The distribution mode of 5-HT-IR cells and the relationship between morphology and function are also discussed.福建省自然科学基金(No.D0320001

福建省动物学学科发展研究报告

1引言动物学是一门具多分支学科的基础科学,不仅学科本身的理论研究内容广博,与农、林、牧、渔、医、工等多方面的实践也有密不可分的关系。纷纭多彩的动物界不仅为人类的衣、食、住、行提供了宝贵资源,也为美化人们的生活、满足人们精神生活的需要提供了丰富内容

东南亚和南亚野生稻种质资源收集与初步研究

目前水稻遗传资源利用已经不能满足水稻现代育种的需求,对其近缘野生种种质资源的开发利用就显得尤为重要。虽然中国具有全世界最多的水稻种质资源储存量,但是近缘野生种(野生稻)种质资源较少,且材料来源分布不均衡,国外野生稻种资源仅占中国水稻近缘野生种种质资源保存量的10%。与中国相比,东南亚和南亚国家野生稻分布区物种丰富,气候条件与我国差异明显,这些地区的野生稻种质资源具有较高的潜在利用价值。本文总结了2009-2019年间对东南亚和南亚10个国家的普通野生稻和尼瓦拉野生稻野外考察结果,共收集2个物种66个群体,1504份个体数;分析了东南亚和南亚野生稻与中国野生稻的生态型差异及其生境特点;提出了未来在东南亚和南亚开展普通野生稻和尼瓦拉野生稻资源收集的重点区域

Reduced Graphene Oxide Electrically Contacted Graphene Sensor for Highly Sensitive Nitric Oxide Detection

<p>We develop graphene-based devices fabricated by alternating current dielectrophoresis (ac-DEP) for highly sensitive nitric oxide (NO) gas detection. The novel device comprises the sensitive channels of palladium-decorated reduced graphene oxide (Pd-RGO) and the electrodes covered with chemical vapor deposition (CVD)-grown graphene. The highly sensitive, recoverable, and reliable detection of NO gas ranging from 2 to 420 ppb with response time of several hundred.. seconds has been achieved at room temperature. The facile and scalable route for high performance suggests a promising application of graphene devices toward the human exhaled NO and environmental pollutant detections. </p

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials

Measurement of integrated luminosity of data collected at 3.773 GeV by BESIII from 2021 to 2024

We present a measurement of the integrated luminosity e+e- of collision data collected by the BESIII detector at the BEPCII collider at a center-of-mass energy of Ecm = 3.773 GeV. The integrated luminosities of the datasets taken from December 2021 to June 2022, from November 2022 to June 2023, and from October 2023 to February 2024 were determined to be 4.995±0.019 fb-1, 8.157±0.031 fb-1, and 4.191±0.016 fb-1, respectively, by analyzing large angle Bhabha scattering events. The uncertainties are dominated by systematic effects, and the statistical uncertainties are negligible. Our results provide essential input for future analyses and precision measurements

Determination of the number of ψ(3686) events taken at BESIII

The number of ψ(3686) events collected by the BESIII detector during the 2021 run period is determined to be (2259.3±11.1)×106 by counting inclusive ψ(3686) hadronic events. The uncertainty is systematic and the statistical uncertainty is negligible. Meanwhile, the numbers of ψ(3686) events collected during the 2009 and 2012 run periods are updated to be (107.7±0.6)×106 and (345.4±2.6)×106, respectively. Both numbers are consistent with the previous measurements within one standard deviation. The total number of ψ(3686) events in the three data samples is (2712.4±14.3)×10^